Carmustine
产品说明书
 |
同义名 : | BCNU;bis-chloroethylnitrosourea;BCNU Becenum;FDA 0345;DTI 015;SRI 1720;SK 27702;Nitrumon;NCI-C04773;NSC 409962;Gliadel;BiCNU |
| CAS号 : | 154-93-8 | |
| 货号 : | A448630 | |
| 分子式 : | C5H9Cl2N3O2 | |
| 纯度 : | 97% | |
| 分子量 : | 214.05 | |
| MDL号 : | MFCD00057706 | |
| 存储条件： |
Pure form Inert atmosphere,Store in freezer, under -20°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 35 mg/mL(163.51 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO H2O: 100 mg/mL(467.18 mM)，配合低频超声助溶 |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Carmustine is an antitumor chemotherapeutic agent, which works by akylating DNA and RNA. NAT (N-acetyltransferase) activity in glial tumor cell cytosols and intact tumor cells were decreased by carmustine in a dose-dependent manner. Carmustine (8, 80, and 800 µM) decreases N-acetyltransferase (NAT) activities for 2-aminofluorene (AF) and p-aminobenzoic acid (PABA) in rat glial tumor cytosol and intact cells. In rat glial tumor cells, the DNA-AF adduct increases, and carmustine decreases the formation of DNA-AF adduct[3]. Preincubation of cells with the glutathione reductase inhibitor, carmustine, led to elevated basal [Ca2+]i, yet the cells remained responsive to bradykinin[4]. Carmustine (≥25 µM) stimulates eryptosis at least partially by increasing cytosolic Ca²⁺ activity[5]. Carmustine (BCNU; 25 mg/kg, i.p.) causes higher levels of the rhe ratio of liver weight to body weight and plasma conjugated bilirubin, and lower biliary flow, oxidised glutation levels (GSSG) and reduced glutation (GSH)/GSSG values compared with control rats[6]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
4.67mL 0.93mL 0.47mL |
23.36mL 4.67mL 2.34mL |
46.72mL 9.34mL 4.67mL |
| 参考文献 |
|---|